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highlights the need to further investigate the infectivity and 
pathophysiology of the virus located in the often neglected 
capillary compartment. These findings provide new infor-
mation on this biologic compartment, which plays a key 
role in vectorborne transmission and transmission dynam-
ics. Moreover, these observations, if validated with more 
patients and extended to other vectorborne infections, will 
be vital for preventing and controlling the transmission of 
Zika virus and other arboviruses.
Institutional review board approval was granted by the Comité 
de Protection des Personnes Sud-Méditerranée I corresponding 
to the following study “Etude descriptive prospective de la  
maladie à virus Zika au sein de la communauté de défense des 
Forces Armées en Guyane” and was registered February 2016 
under the number RCB: 2016-A00394-47. Written informed  
consent was obtained from each patient as required by the  
Comité de Protection des Personnes Sud-Méditerranée I.
This work was funded by the Direction Centrale du Service de 
Santé des Armées (grant agreement 2016RC10) and supported 
by the European Virus Archive Goes Global project, which has 
received funding (grant agreement 653316) from the European 
Union’s Horizon 2020 Research and Innovation Program. Funding 
sources played no role in study design, patient recruitment, data 
collection, analysis and interpretation of the data, or writing of the 
manuscript or the decision to submit it for publication.
Dr. Matheus is a research assistant at the Institute Pasteur 
de la Guyane, French Guiana, with research interests in 
the diagnosis and pathophysiology of arboviruses. She is 
currently studying viral emergence, particularly that of a 
hantavirus in French Guiana.
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After conventional molecular and serologic testing failed to 
diagnose the cause of illness, deep sequencing identified 
spotted fever group Rickettsia DNA in a patient’s blood sam-
ple. Sequences belonged to R. honei, the causative agent 
of Flinders Island spotted fever. Next-generation sequenc-
ing is proving to be a useful tool for clinical diagnostics.
When conventional laboratory tests cannot identify an etiologic agent, unbiased deep sequencing performed 
directly on a clinical sample has the potential to identify a 
probable cause of disease. We used deep sequencing to de-
tect spotted fever group (SFG) Rickettsia DNA in the blood 
of a patient for whom diagnosis was not possible through 
conventional molecular and serologic testing.
In late 2016, a middle-aged woman was admitted to a 
regional hospital in Queensland, Australia, after 2 weeks of 
mild cough, myalgia, fever, and lethargy. The day before ad-
mission, she experienced a blanching rash and pains in her 
feet, after which her condition deteriorated and a definite 
petechial rash appeared. Chest radiographs showed atelec-
tasis on 1 side. Meningococcal septicemia was suspected, 
and the patient was transferred to intensive care with septic 
shock. Despite treatment with inotropes and several antimi-
crobial drugs (including ceftriaxone, vancomycin, merope-
nem, doxycycline), the patient died the next morning.
Clinical testing did not identify an infectious dis-
ease agent in the patient’s blood; serologic test results 
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for Rickettsia were negative. Because a limited amount 
of specimen remained for testing, we applied an unbiased 
deep-sequencing approach. We extracted DNA from the 
blood sample by using the MasterPure Complete DNA 
Purification Kit (Epicenter, Madison, WI, USA) and se-
quenced with the Ion Torrent PGM (Personal Genome 
Machine) workflow by using the Ion PGM IC 200 Kit 
and the Ion 316 Chip Kit, version 2 (Life Technologies, 
Carlsbad, CA, USA). A total of 3,627,903 sequences were 
generated and trimmed by using a minimum quality score 
of Q15 and minimum length of 50 bp. Of the reads gen-
erated, 251 matched bacterial DNA sequences (uploaded 
to GenBank as Bioproject PRJEB21107). The rest either 
matched human genome sequences and were filtered out 
(3,619,386 reads) or were unclassified (8,252 reads). 
We analyzed the reads for bacterial DNA by using 3 
metagenomics tools: Kraken (1), PathoScope (2), and One 
Codex (https://www.onecodex.com). All 3 analyses re-
turned similar results; ≈80% of classified reads (208/251 
reads, 53,958 total nucleotides) matched sequences from 
SFG Rickettsia spp.; the remainder gave low-number, low-
quality matches to other bacteria. Screening of reads for 
sequences matching 5 rickettsial genes (rrs, ompA, ompB, 
gltA, and sca4) found 1 read mapping to the ompB gene 
(online Technical Appendix, https://wwwnc.cdc.gov/EID/
article/23/11/17-0474-Techapp1.pdf). This read was a 
100% match (272/272 nt) to R. honei ompB (GenBank ac-
cession nos. AF123724.1, AF123711.1). The next highest 
match was to R. parkerii ompB (accession no. KY113111.1) 
at 99% (270/272 nt). We confirmed the presence of SFG 
Rickettsia DNA in the DNA extract of the sample by nested 
PCR and performed Sanger sequencing by using the Invit-
rogen SuperScript III One-Step RT-PCR system with prim-
ers (3) and in-house nested primers.
To narrow down the identification to species level, we 
further analyzed sequences matching Rickettsia spp. We 
downloaded all Rickettsia genomes available at the Na-
tional Center for Biotechnology Information (https://www.
ncbi.nlm.nih.gov/), complete and draft, and used them 
as reference sequences for mapping of the reads in CLC 
Genomics Workbench 8 (QIAGEN Aarhus, Silkeborgvej, 
Denmark). We discarded reads mapping to >1 genome, col-
lected the remaining reads that mapped uniquely to a single 
genome, and noted the genome to which they mapped. Of 
the 208 reads, 67 mapped to >1 genome, 1 did not map 
to any of the genomes and was subsequently identified 
as matching that of the human reference genome, 3 were 
unique matches to R. conorii (AJUR01, GenBank acces-
sion no. NC_003103), 1 was a unique match to R. sibirica 
(accession no. NZ_AHZB01000018), and 151 were unique 
matches to R. honei (accession no. NZ_AJTT00000000) 
(online Technical Appendix) (4). Mapping of the 208 se-
quencing reads revealed that 207 (99.6%) reads mapped 
to the R. honei genome, giving 1.43% coverage of the ge-
nome, and 168 (80.7%) reads mapped to the R. australis 
(accession no. NC_017058) genome, representing 0.03% 
coverage of the genome.
The main causes of SFG rickettsioses in Australia 
are R. australis and R. honei, which cause Queensland 
tick typhus and Flinders Island spotted fever, respectively 
(5). The rickettsial DNA in the blood sample we describe 
most closely matched sequences from R. honei and had a 
relatively low level of similarity to sequences from R. aus-
tralis. R. honei was initially reported only in the southern 
states of Australia; however, a genetic variant known as 
the “marmionii” strain has since been reported in eastern 
and northern parts of the country (6). Unfortunately, the 
genome of R. honei “marmionii” has not been sequenced, 
and the genes used to differentiate between R. honei and R. 
honei “marmionii” were not covered by the sequences gen-
erated from the sample. Therefore, we could not confirm 
which strain of R. honei was in the sample.
Flinders Island spotted fever is reportedly associated 
with relatively mild illness (5). However, our detection of 
R. honei DNA in the blood of a deceased patient, in the 
absence of positive Rickettsia serologic test results, is sug-
gestive of acute infection with this agent. This case dem-
onstrates the potential of deep sequencing for identifying 
unknown etiologic agents, particularly when other methods 
have not done so.
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We detected Chlamydia trachomatis biovar L2 in vaginal 
swab specimens of 7 women with vaginal discharge in 
South Africa. Whole-genome sequencing directly from clini-
cal specimens identified a closely related cluster of strains. 
The clinical role of this infection in the context of syndromic 
management should be clarified.
Infection with Chlamydia trachomatis biovar L is known as lymphogranuloma venereum (LGV). This infection 
usually presents as genital ulcers, followed by an inva-
sion of the lymphatic system resulting in buboes, painful 
swelling of lymph nodes (1). In the past 2 decades, another 
manifestation of LGV has emerged in North America and 
Europe: rectal LGV infection causing proctocolitis among 
men who have sex with men (MSM) (1). In this population, 
urethral LGV also occurs (2).
There have been only sporadic reports of rectal and 
genital LGV infection in women living in the industri-
alized world (3,4). Cross-sectional studies from France, 
Switzerland, and the Netherlands did not detect biovar L 
in specimens from women with genital or rectal C. tra-
chomatis infection (1,5–7). Because lymphatic manifes-
tation has become relatively rare, LGV infection is con-
sidered an outbreak mainly among MSM in Europe and 
North America (1). Lymphatic LGV is endemic to Africa, 
but before our study, it was unknown whether C. tracho-
matis biovar L infections occurred in women in Africa. 
Thus, we determined the prevalence of this infection in 
South Africa. 
To determine whether genital C. trachomatis biovar 
L infections occur in women living in South Africa, we 
analyzed 82 DNA samples extracted from vaginal swab 
specimens that were positive by a molecular detection 
assay for C. trachomatis infection at the Department 
of Medical Microbiology at the University of Pretoria. 
The Faculty of Health Sciences Research Ethics Com-
mittee at the University of Pretoria approved the stud-
ies in which these specimens were collected. These 
swab specimens had been collected during 2012–2016 
from women attending different healthcare settings: a 
mobile health clinic in rural Mopani District (n = 52) 
and 3 departments at the academic hospital in Pretoria: 
obstetrics and gynecology clinic (n = 14), antiretroviral 
treatment clinic (n = 10), and sexually transmitted in-
fection (STI) clinic (n = 6). We assessed the presence 
of LGV in these genital specimens by using specific 
PCRs for C. trachomatis serovar L and serovar L2b (8). 
For positive PCR results, we confirmed the diagnosis 
by conducting whole-genome sequencing (WGS) of C. 
trachomatis directly from the clinical specimen as de-
scribed elsewhere (9).
Whereas C. trachomatis biovar L–specific PCR 
showed positive results for 7 specimens obtained from 
women at the antiretroviral treatment  (n = 5) and STI (n = 
2) clinics in Pretoria, we did not detect LGV in any of the 
52 specimens from women in Mopani District. All PCR test 
results for serovar L2b were negative. The 7 women with 
genital LGV all had vaginal discharge and were co-infected 
with another STI (Table).
WGS confirmed LGV (ompA sequence identical to 
those of the C. trachomatis L2 434/BU reference strain) in 
4 cases with good mean read depth (>12) and high genome 
coverage (>98%). The 4 sequences clustered well with 
the L2 sequences previously published and away from L1 
and L2b sequences. For 1 specimen, the mean read depth 
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